Top

CCMB Finds Compounds For Preventing Deadly Fungal Infections

The team also found that one of the compounds reduced biofilm formation in laboratory tests: Reports

HYDERABAD: Scientists from Hyderabad-based the CSIR-Centre for Cellular and Molecular Biology (CCMB) have identified two compounds that can prevent a deadly fungal pathogen from transforming into its disease-causing form, opening up a potential new approach to treating fungal infections.

The study, led by Dr Sriram Varahan, focuses on Candida albicans, a single-celled fungus (yeast) commonly found on the skin and inside the human body, which can cause serious infections when it enters the bloodstream or internal organs.

The fungus changes its shape from round cells into long filaments, enabling it to evade the immune system and cause infections. The researchers found that two compounds targeting glycolysis, the pathway through which cells metabolise sugar, could inhibit this transformation. Though the fungus continued to grow, it remained in its rounded form, which is less associated with infection.

The findings, which have been published in the journal ‘ACS Infectious Diseases’, highlight pyruvate kinase, an enzyme involved in glycolysis, as a potential target for controlling the fungus' disease-causing behaviour.

The team also found that one of the compounds reduced biofilm formation in laboratory tests. Biofilms protect the fungus from antifungal medicines. The compound also increased its sensitivity to existing drugs, including fluconazole and amphotericin B. In a mouse model of systemic Candida infection, treatment with a lead compound significantly improved survival.

Dr Varahan said the compounds provided starting points for further research into how metabolic pathways could be used to disrupt fungal behaviour associated with infections. He cautioned that more studies were needed to understand their mechanisms, improve their properties and assess their safety and suitability for treatment.

Dhrumi Shah, the first author of the study, said the findings suggested that disease-causing behaviour in fungi could be targeted without necessarily stopping their growth.

The study — conducted by CSIR-CCMB scientists in collaboration with researchers from BRIC-Translational Health Science and Technology Institute (THSTI) — proposes an approach that could complement existing antifungal treatments at a time when fungal infections are increasing and the number of available antifungal drugs remains limited. The compounds are still research candidates and are not approved medicines.


( Source : Deccan Chronicle )
Next Story